MedTrace Logo

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

NCT00880074 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-06-26

No results posted yet for this study

Summary

This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors and measure a patient's response to treatment.

Conditions

  • Malignant Neoplasm

Interventions

DRUG

Fluorothymidine F-18

Undergo fluorine F-18 fluorothymidine PET

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

PROCEDURE

Positron Emission Tomography

Undergo fluorine F-18 fluorothymidine PET

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Sarina A Piha-Paul · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-09
Primary Completion
2022-02-04
Completion
2022-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00880074 on ClinicalTrials.gov